The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | The genomic definition of high-risk myeloma
Jill Corre, PhD, The Cancer University Institute of Toulouse Oncopole, Toulouse, France, discusses the genomic markers of high-risk myeloma as defined by the IMS consensus. She identifies key gene mutations in high-risk myeloma, including deletion 17p, TP53 mutations, deletion 1p32, high-risk IGH translocations, and gain 1q. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
